{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:09:29Z","timestamp":1791468569407,"version":"4.3.4"},"reference-count":30,"publisher":"Massachusetts Medical Society","issue":"9","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les Hepatites Virales","doi-asserted-by":"publisher","award":["ANRS12314"],"award-info":[{"award-number":["ANRS12314"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UNITAID","award":["NAMSAL Trial"],"award-info":[{"award-number":["NAMSAL Trial"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2019,8,29]]},"DOI":"10.1056\/nejmoa1904340","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T15:13:15Z","timestamp":1563981195000},"page":"816-826","source":"Crossref","is-referenced-by-count":308,"title":["Dolutegravir-Based or Low-Dose Efavirenz\u2013Based Regimen for the Treatment of HIV-1"],"prefix":"10.1056","volume":"381","author":[{"name":"The NAMSAL ANRS 12313 Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","unstructured":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization December 2018 (https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277395\/WHO-CDS-HIV-18.51-eng.pdf?ua=1)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_5_4_2","unstructured":"Clinton Health Access Initiative. ARV market report: the state of the antiretroviral drug market in low- and middle-income countries 2016\u20132021. September 2017 (https:\/\/clintonhealthaccess.org\/content\/uploads\/2017\/09\/2017-ARV-Market-Report_Final.pdf)."},{"key":"e_1_3_5_5_2","unstructured":"World Health Organization. Statement on DTG. May 18 2018 (http:\/\/www.who.int\/medicines\/publications\/drugalerts\/Statement_on_DTG_18May_2018final.pdf?ua=1)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000445"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30277-6"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70255-9"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30702-8"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62187-X"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy161"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy491"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30331-X"},{"key":"e_1_3_5_15_2","unstructured":"Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance document: human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. November 2015 (http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM355128.pdf)."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60917-9"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60918-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286151104500309"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1348\/014466505X29657"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-10-200511150-00008"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00449-8"},{"key":"e_1_3_5_24_2","unstructured":"Stanford University. HIV drug resistance database algorithm version 8.8. 2019 (https:\/\/hivdb.stanford.edu)."},{"key":"e_1_3_5_25_2","unstructured":"Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: non-inferiority clinical trials. November 2016 (http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM202140.pdf)."},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f5556d"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835b105e"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky005"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv012"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/v10010041"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1904340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:34:35Z","timestamp":1711499675000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1904340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,8,29]]}},"alternative-id":["10.1056\/NEJMoa1904340"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa1904340","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]}}}